Company Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed OTC Markets Other stock markets 02:42:51 2024-04-25 pm EDT			5-day change	1st Jan Change
0.019 ^USD	+22.58%		+14.46%	-95.40%

Apr. 10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
Apr. 05	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Number of employees: 147

Managers	Title	Age	Since
Abbey Jenkins CEO	Chief Executive Officer	-	22-09-16
Mary Coelho DFI	Director of Finance/CFO	62	23-05-21
Joshua Patterson CMP	Compliance Officer	48	21-07-31
Yona Geffen CTO	Chief Tech/Sci/R&D Officer	-	20-11-30
Ronit Simantov CTO	Chief Tech/Sci/R&D Officer	59	17-06-30
Julian Adams BRD	Director/Board Member	69	16-07-31
Vladimir Melnikov PRN	Corporate Officer/Principal	-	21-06-05
Yisrael Gewirtz AUD	Comptroller/Controller/Auditor	47	-

Members of the board	Title	Age	Since
Stephen Wills BRD	Director/Board Member	67	19-05-31
Kenneth Moch BRD	Director/Board Member	69	16-06-30
Julian Adams BRD	Director/Board Member	69	16-07-31
Shawn Tomasello CHM	Chairman	65	19-05-31
Abbey Jenkins CEO	Chief Executive Officer	-	22-09-16
Ivan Borrello BRD	Director/Board Member	60	22-06-08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	154,203,434	137,879,757 ( 89.41 %)	152,481 ( 0.0989 %)	89.41 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 6.063 %	8,042,172	6.063 %	289 518 $
Heights Capital Management, Inc. 5.252 %	6,966,279	5.252 %	250 786 $
Levin Capital Strategies LP 4.541 %	6,023,629	4.541 %	216 851 $
Community US Fund Management, Inc. 3.897 %	5,169,471	3.897 %	186 101 $
NOVARTIS AG 3.270 %	4,336,759	3.270 %	156 123 $
Levin Capital Strategies LP 2.826 %	3,747,827	2.826 %	134 922 $
MEITAV INVESTMENT HOUSE LTD 2.756 %	3,655,158	2.756 %	131 586 $
CLAL BIOTECHNOLOGY INDUSTRIES LTD. 1.946 %	2,581,746	1.946 %	92 943 $
Millennium Management LLC 1.937 %	2,568,866	1.937 %	92 479 $
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Ltd. 1.668 %	2,211,981	1.668 %	79 631 $

Gamida Cell Ltd.

116 Huntington Avenue

02116, Boston

http://www.gamida-cell.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.0155 USD

Average target price

6 USD

Spread / Average Target

+38,609.68%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
GAMIDA CELL LTD.	-95.40%	2.39M
VERTEX PHARMACEUTICALS INCORPORATED	-2.02%	104B
REGENERON PHARMACEUTICALS, INC.	+1.67%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.68%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.01%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.70%	13.98B
SAREPTA THERAPEUTICS, INC.	+33.51%	11.66B

Bio Therapeutic Drugs